체외수정(IVF) 기기 및 소모품 시장 : 제품 유형별, 시술 유형별, 기술별, 최종 사용자별, 환자 유형별, 유통 채널별 시장 예측(2026-2032년)

The In-Vitro Fertilization Devices & Supplies Market is projected to grow by USD 6.59 billion at a CAGR of 12.51% by 2032.

In-vitro fertilization devices and supplies underpin every stage of assisted reproductive technology, from oocyte retrieval and sperm preparation to embryo culture, cryostorage, biopsy, and transfer. Demand is supported by a well-documented infertility burden: the World Health Organization estimates that roughly 1 in 6 adults experience infertility during their lifetime, making access to safe, effective IVF equipment, consumables, and laboratory systems a public health and clinical capacity priority.

The market is shaped by rising maternal age, improved fertility diagnostics, broader fertility preservation, and expanding use of vitrification, time-lapse incubation, micromanipulation tools, embryo transfer catheters, culture media, and laboratory consumables. Growth is increasingly tied to product quality, contamination control, regulatory compliance, chain-of-custody safeguards, and measurable improvements in lab workflow and reproductive outcomes.

Transformative Shifts in the IVF Devices Landscape

The IVF devices and supplies landscape is moving from procedure-centric purchasing toward integrated embryology laboratory ecosystems. Clinics increasingly evaluate incubators, micromanipulators, imaging systems, cryopreservation equipment, labware, media, and witnessing systems as interconnected components that influence consistency, traceability, and patient safety.

Regulation is also reshaping procurement. The EU Medical Device Regulation, U.S. FDA quality system expectations, and country-level ART rules are raising standards for documentation, biocompatibility, sterility assurance, risk management, and post-market surveillance. At the same time, fertility centers are expanding capacity through automation, digital lab management, closed-system vitrification, electronic witnessing, and standardized consumables to reduce variability across high-volume programs.

Cumulative Impact of Artificial Intelligence in IVF

Artificial intelligence is becoming a practical layer in IVF workflows, particularly in embryo assessment, image analysis, sperm selection research, laboratory quality control, and predictive decision support. AI-enabled time-lapse embryo evaluation can standardize visual scoring and help embryologists prioritize embryos, while digital witnessing and analytics can reduce manual errors in complex laboratory environments.

The cumulative impact is operational rather than fully autonomous. Current evidence supports AI as an adjunct to trained clinical and embryology teams, not a replacement for professional judgment. Successful adoption depends on validated datasets, transparent performance metrics, bias monitoring, regulatory clearance where required, cybersecurity, data governance, and integration with electronic medical records and laboratory information systems.

Key Regional Insights Across Global IVF Markets

Asia-Pacific is one of the most dynamic IVF devices and supplies regions, supported by large patient pools, medical tourism, expanding fertility networks, and strong procedure activity in China, India, Japan, South Korea, and Australia. Japan and Australia have mature ART reporting systems, South Korea combines advanced healthcare infrastructure with demographic pressure from very low fertility, and India's Assisted Reproductive Technology Regulation Act has strengthened oversight of clinics and gamete banks, reinforcing demand for compliant IVF devices, culture media, cryostorage systems, and traceable consumables.

North America benefits from high technology adoption, advanced cryostorage infrastructure, and strong private fertility networks. Europe remains highly regulated and clinically mature, supported by ESHRE monitoring, national registries, tissue and cell standards, and strong adoption of vitrification and embryology laboratory quality systems. Latin America is expanding through Brazil and Mexico, where private fertility centers and cross-border care support demand for reliable IVF supplies. The Middle East shows selective growth led by GCC healthcare investment, urban specialty clinics, and demand for fertility preservation, while Africa remains uneven but is progressing through metropolitan fertility centers, physician training, and rising awareness of infertility as a healthcare need.

Key Group Insights for IVF Devices & Supplies

ASEAN fertility demand is rising as urbanization, delayed parenthood, and private healthcare investment support new IVF centers in Singapore, Thailand, Malaysia, Vietnam, Indonesia, and the Philippines. The region's opportunity is closely linked to affordability, accreditation, laboratory training, medical travel, and cross-border reproductive care, creating sustained need for IVF incubators, micromanipulation equipment, embryo transfer supplies, vitrification kits, and quality-controlled consumables.

The GCC is investing in premium fertility infrastructure, with strong demand for controlled ovarian stimulation support, cryostorage, advanced imaging, and high-quality embryology consumables. The European Union remains a benchmark for regulatory rigor under EU MDR and tissue and cell directives, making documented quality systems essential for suppliers. BRICS countries combine scale with uneven access, creating opportunities for cost-efficient supplies, domestic manufacturing, and training-driven standardization. G7 markets lead in premium IVF equipment, AI-enabled laboratory tools, and established quality governance, while NATO economies broadly benefit from advanced healthcare systems, procurement discipline, and quality-driven supplier qualification that favor validated, traceable, and compliant IVF devices and supplies.

Key Country Insights in Major IVF Markets

The United States leads in private fertility service innovation, with strong demand for time-lapse incubators, vitrification tools, electronic witnessing, and advanced lab consumables; CDC surveillance confirms ART's measurable contribution to national births and underscores the importance of standardized reporting. Canada emphasizes quality and provincial funding variation, while Mexico and Brazil serve both domestic and cross-border patients through expanding private fertility networks. The United Kingdom is shaped by HFEA oversight, and Germany, France, Italy, and Spain combine strict regulation with established ART networks, with Spain widely recognized for reproductive medicine capacity and international patient flows.

Russia maintains large urban IVF capacity despite supply-chain complexity and changing procurement conditions. China's licensed fertility centers serve substantial demand under regulated access, while India is scaling under a newer ART regulatory framework that increases the importance of compliant devices, gamete bank oversight, and clinic documentation. Japan faces sustained demographic pressure from low fertility and advanced maternal age, South Korea's national policy focus on fertility and reproductive healthcare supports ART utilization, and Australia remains a high-transparency market with strong registry reporting, clinical governance, and demand for validated laboratory systems and IVF consumables.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize validated performance, supply continuity, and regulatory readiness. IVF clinics increasingly require devices and consumables with documented sterility, low volatile organic compound exposure, consistent lot performance, embryo-safe materials, and compatibility with closed or semi-closed laboratory workflows. Suppliers that provide training, preventive maintenance, validation documentation, and traceability support can strengthen long-term customer retention.

Manufacturers should invest in AI-ready imaging platforms, interoperable lab systems, sustainable packaging, robust cold-chain and cryostorage support, and region-specific regulatory dossiers. Commercial teams should segment customers by procedure volume, reimbursement environment, regulatory maturity, and embryology capability, then align offerings with measurable outcomes such as workflow efficiency, cryosurvival, contamination reduction, error prevention, and quality management compliance.

Research Methodology for IVF Market Analysis

This executive summary is grounded in triangulated secondary research from recognized public health, regulatory, and professional sources, including WHO infertility estimates, CDC ART reporting, ESHRE monitoring, HFEA publications, EU medical device rules, and national ART regulatory frameworks. Market interpretation also reflects observed adoption patterns in fertility clinics, embryology laboratories, cryopreservation workflows, and quality management practices.

The analysis emphasizes verified structural drivers rather than unsubstantiated forecasts. Regional, group, and country insights were assessed using healthcare infrastructure, ART reporting maturity, regulatory environment, fertility demographics, clinical capacity, reimbursement context, and technology adoption. Findings were synthesized to support strategic decision-making for device manufacturers, consumable suppliers, distributors, and fertility service networks.

Conclusion: Strategic Outlook for IVF Devices & Supplies

The in-vitro fertilization devices and supplies market is advancing from stand-alone product procurement to integrated, quality-controlled reproductive laboratory platforms. Rising infertility prevalence, delayed parenthood, fertility preservation, and expanding ART access continue to support demand for reliable IVF equipment, culture media, cryopreservation systems, catheters, micromanipulation tools, witnessing solutions, and laboratory consumables.

Competitive advantage will depend on clinical credibility, regulatory compliance, workflow integration, supply resilience, and evidence-based innovation. Companies that combine dependable IVF supplies with AI-enabled decision support, training, traceability, and regional market adaptation will be best positioned to serve fertility clinics seeking safer, more consistent, and scalable IVF outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. In-Vitro Fertilization Devices & Supplies Market, by Product Type

• 7.1. Consumables & Supplies
• 7.2. Devices
  • 7.2.1. Anti-vibration Tables
  • 7.2.2. Cryopreservation Equipment
  • 7.2.3. Embryo Transfer Catheters
  • 7.2.4. Gas Analyzers
  • 7.2.5. Heating Stages & Warmers
  • 7.2.6. ICSI Micromanipulation Systems
  • 7.2.7. Incubators
  • 7.2.8. Laser Systems
  • 7.2.9. Microscopes
  • 7.2.10. Ovum Aspiration Pumps
  • 7.2.11. Sperm Analyzer Systems
  • 7.2.12. Witness Verification Systems

8. In-Vitro Fertilization Devices & Supplies Market, by Procedure Type

• 8.1. Cryopreservation
• 8.2. Embryo Culture & Assessment
• 8.3. Embryo Transfer
• 8.4. Fertilization
• 8.5. Oocyte Retrieval
• 8.6. Ovulation Induction
• 8.7. Sperm Collection & Processing

9. In-Vitro Fertilization Devices & Supplies Market, by Technology

• 9.1. Donor Egg IVF
• 9.2. Fresh Embryo IVF
• 9.3. Frozen Embryo IVF

10. In-Vitro Fertilization Devices & Supplies Market, by End User

• 10.1. Ambulatory Surgical Centers
• 10.2. Cryobanks / Biobanks
• 10.3. Fertility Clinics
• 10.4. Hospitals
• 10.5. Research & Academic Institutes

11. In-Vitro Fertilization Devices & Supplies Market, by Patient Type

• 11.1. Female Infertility
  • 11.1.1. Endometriosis
  • 11.1.2. Ovulatory Disorders
  • 11.1.3. Tubal Factor Infertility
  • 11.1.4. Unexplained Infertility
• 11.2. Male Infertility
  • 11.2.1. Abnormal Morphology
  • 11.2.2. Low Sperm Count
  • 11.2.3. Poor Motility

12. In-Vitro Fertilization Devices & Supplies Market, by Distribution Channel

• 12.1. Offline
• 12.2. Online

13. In-Vitro Fertilization Devices & Supplies Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. In-Vitro Fertilization Devices & Supplies Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. In-Vitro Fertilization Devices & Supplies Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. AIVF Ltd.
• 17.2. Analis sa
• 17.3. ASB Medical System Pvt. Ltd.
• 17.4. Avantor, Inc.
• 17.5. Carl Zeiss AG
• 17.6. Cook Medical LLC
• 17.7. CooperSurgical, Inc.
• 17.8. Corning Incorporated
• 17.9. Eppendorf SE
• 17.10. Esco Group
• 17.11. Fertipro NV
• 17.12. FUJIFILM Irvine Scientific, Inc.
• 17.13. Genea Biomedx Pty Ltd
• 17.14. Getner Instruments Pvt. Ltd.
• 17.15. Hamilton Thorne, Inc.
• 17.16. Hunter Scientific Limited
• 17.17. IVFtech ApS
• 17.18. Leica Microsystems GmbH
• 17.19. Nidacon International AB
• 17.20. Nikon Corporation
• 17.21. Olympus Corporation
• 17.22. Overture Life, S.L.
• 17.23. Shivani Scientific Industries Limited.
• 17.24. Thermo Fisher Scientific Inc.
• 17.25. Vitrolife Sweden AB